American College of Cardiology (ACC)

The American College of Cardiology (ACC) is the primary U.S. medical society representing the interests of all cardiology subspecialities. The ACC is very active in setting guidelines for cardiac care, lobbying for supportive government policy and reimbursements, clinician education, managing several key cardiovascular registries and advocating for the transformation of cardiovascular care to improve heart health.

RSS icon
lex Sandhu, MD, MS, assistant professor of cardiovascular medicine, Stanford University, and cardiologist at the Palo Alto VA. He spoke in the business of cardiology sessions at ACC 2024 and explained how Medicare reimbursements will be moving toward a value based payment model by 2030. #ACC #ACC24 #ACC2024 #CMS #reimbersements #Medicare

How the shift to value-based reimbursements could transform cardiology

"I think we really need our cardiologist community to understand the changes that are happening with value-based payment," one expert tells Cardiovascular Business. 

heart patient

New hypertrophic cardiomyopathy guidelines highlight importance of exercise, new drug class

HCM is widely underdiagnosed, but the American College of Cardiology and American Heart Association hope their new guidelines can help cardiologists learn more about the potentially fatal condition and improve patient care. 

Interview with Nehal Mehta, MD, Penn Medicine, who explains how coronary inflammation can be seen using AI on cardiac CT scans to better risk stratify patients and begin preventive drug therapy.

AI helps cardiologists track new drug's effect on inflammation

The combination of AI and CT helped Nehal Mehta, MD, and colleagues track the performance of a new drug designed to target coronary inflammation. 

Jeff Kuvin, MD, explains the effort to create an new independent cardiology board. He is the ACC point person for the effort.

The push for an independent cardiology board continues

Jeffrey Kuvin, MD, one of the leading voices behind efforts to create a new Board of Cardiovascular Medicine, spoke with Cardiovascular Business about where things stand today.

ACC President Cathie Biga explains how cardiologist employment models undergoing a profound transformation during an interview with Cardiovascular Digital Editor Dave Fornell at ACC 2024.

What happened to cardiology's private practices?

Hospital employment models, reimbursement policies and private equity have all led to a massive reduction in the number of cardiologists working for a private practice, ACC President Cathie Biga, MSN, told Cardiovascular Business.

First-in-Man Experience of Robotic-Assisted Transcatheter Edge-to-Edge Repair With Pure Echo Guidance

Cardiologists and surgeons perform world’s first robot-assisted TEER

A 62-year-old women presented with severe MR and recurrent heart failure episodes. Initial data suggest the procedure was a success.

Sunil Rao, MD, NYU, explains the DANGER-SHOCK trial at ACC 2024 and how it may help improve cardiogenic shock survival.

Cardiologist Sunil Rao highlights importance of DanGer Shock compared to other cardiogenic shock trials

Sunil Rao, MD, director of interventional cardiology at NYU Langone, says DanGer Shock is a "very, very important study" when it comes to the treatment of cardiogenic shock. 

An 86-year-old patient is showing signs of improvement six months after receiving the world’s first implant of a new-look medical device for treating tricuspid regurgitation (TR), according to new data published in JACC: Cardiovascular Interventions.[1] The device in question, the Tricuspid Flow Optimizer, was developed by Triflo Cardiovascular, a U.S.-based biomedical company founded in 2017 by a team of structural heart specialists.

Cardiologists share update after world’s first implant of new optimizer device for tricuspid regurgitation

The Tricuspid Flow Optimizer was developed by Triflo Cardiovascular, a U.S.-based healthcare technology company founded by structural heart specialists.

Displaying 169 - 176 of 399
Design by Adaptive Theme